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Background: This two decade long study presents a comprehensive overview of theCFTRmutation distribution in a representative cohort of 600Czech
CF patients derived from all regions of the Czech Republic.
Methods: We examined the most common CF-causing mutations using the Elucigene CF-EU2v1™ assay, followed by MLPA, mutation scanning
and/or sequencing of the entire CFTR coding region and splice site junctions.
Results: We identiﬁed 99.5% of all mutations (1194/1200 CFTR alleles) in the Czech CF population. Altogether 91 different CFTR mutations, of
which 20 were novel, were detected. One case of de novo mutation and a novel polymorphism was revealed.
Conclusion: The commercial assay achieved 90.7%, the MLPA added 1.0% and sequencing increased the detection rate by 7.8%. These
comprehensive data provide a basis for the improvement of CFDNA diagnostics and/or newborn screening in our country. In addition, they are relevant
to related Central European populations with lower mutation detection rates, as well as to the sizeable North American “Bohemian diaspora”.
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Poland; SK, Slovak/Slovakia; UK, United Kingdom; USA, United States of America.
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The incidence of cystic fibrosis (CF) in the Czech Republic
(CZ) was estimated using epidemiological approaches more
than half a century ago (1 in 2700 live births), while recent
outcomes of a nationwide CF newborn screening (NBS)
revealed a two-fold lower incidence (1 in 4023 live births) [1].
Given the current annual birth rate of 108,673 [2], approx-
imately 30 CF patients would be expected to be born each year.
The CZ population has German (Bavarian; DE), Northern
Austrian (AT), Polish (PL), Slovak (SK) or Hungarian (HU)
influences (arranged by the degree of their historical impact)
and is a representative of the population composition of Central
Europe (CE) [3,4]. Romani intermarriage and non-European
immigration have remained marginal [2]. Therefore, generally
speaking, the CZ population is stable and homogeneous [5].
Over the past two decades, the Prague CF Centre has performed
DNA diagnostic testing for the cystic fibrosis transmembrane
conductance regulator (CFTR) gene in a group of almost 3000 CZ
families. This facility serves as the national reference center, both
for clinical and laboratory diagnosis of CF [6], within an official
network of regional CF centers [7]. The Prague center also
coordinates CF newborn screening for the western part of the
country [1].
The aim of this study is to present results from a substantially
larger and representative group of CZ CF patients, compared toFig. 1. Origin of 600 Czech CF patients. Legend: Origin of patients is based on the posta
Region — 99; Central Bohemia Region (i.e. regiona surrounding Prague) — 88; Ústí
South-Bohemian (České Budějovice) Region— 40; Hradec Králové Region— 37; Zlí
29; Vysočina (Jihlava) Region— 29; Karlovy Vary Region— 26; Olomouc Region—the previous report published within a collaborative study [8]. In
addition, data on intra-CFTR rearrangements, copy number and/or
novel mutations are included. Significantly updated data provide
a basis for improvement of CF DNA diagnosis and/or CF NBS in
the CZ and related populations. Finally, the information is
important for the selection of patients for mutation-specific
therapies [9].
2. Methods
Diagnosis of CF was established in 600 unrelated CZ CF
patients by using a combination of clinical and laboratory
diagnostic criteria [10]. Their geographic origin is presented in
Fig. 1. During this long-term population study, DNA diagnostic
techniques have gradually evolved (data available upon request).
Initially, we examined the most common CF causing mutations
using “in house” methods, later followed by commercial assays
(e.g. Elucigene CF-EU2v1™, Gen-Probe Life Sciences, UK).
Patients with one or both unidentified mutations were then
examined for intragenic rearrangements using multiplex ligation-
dependent probe amplification (MLPA, MRC-Holland, Nether-
lands). Subsequently, negative cases were subjected to mutation
scanning [11] and/or sequencing of the entireCFTR coding region
and splice site junctions (Applied Biosystems, USA). Any
detected CFTR mutations were verified in the index case's
parents.l codes of their domicile. Number of patients in the regions: Capital Prague (Praha)
nad Labem Region — 52; Pilsen (Plzeň) Region — 48; Liberec Region— 41;
n Region— 32; Pardubice Region— 31; Moravian-Silesian (Ostrava) Region—
25; South Moravian (Brno) Region— 23.
Table 1
Spectrum of CFTR mutations detected in Czech CF patients.
Mutations/HGVS nomenclature/ Mutations/traditional nomenclature, legacy name/ Legacy exon/intron No. of alleles %
1. c.1521_1523delCTT F508del*# Ex10 809 67.42
2. c.54-5940_273+10250del21kb CFTRdele2,3/21kb/*# In1–In3 69 5.75
3. c.1652GNA G551D*# Ex11 35 2.92
4. c.3909CNG N1303K*# Ex21 29 2.42
5. c.1624GNT G542X*# Ex11 24 2.00
6. c.3718-2477CNT 3849+10kbCNT*# In19 20 1.67
7. c.1766+1GNA 1898+1GNA*# In12 17 1.42
8. c.1040GNC R347P*# Ex7 11 0.92
9. c.2012delT 2143delT*# Ex13 11 0.92
10. c.3140-26ANG 3272-26ANG*# In17a 8 0.67
11. c.1007TNA I336K# Ex7 7 0.58
12. c.3846GNA W1282X*# Ex20 7 0.58
13. c.1657CNT R553X*# Ex11 6 0.50
14. c.2657+5GNA 2789+5GNA*# In14b 6 0.50
15. c.2834CNT S945L# Ex15 6 0.50
16. c.442delA 574delA# Ex4 5 0.42
17. c.489+1GNT 621+1GNT*# In4 5 0.42
18. c.2052_2053insA 2184insA# Ex13 5 0.42
19. c.3009_3017delAGCTATAGC 3141del9& Ex17a 5 0.42
20. c.366TNA Y122X*# Ex4 4 0.33
21. c.[874GNA]+[2126GNA] E292K/R709Q Ex7/Ex13 4 0.33
22. c.1585-1GNA 1717-1GNA*# In10 4 0.33
23. c.3454 GNC D1152H*# Ex18 4 0.33
24. c.3484CNT R1162X*# Ex19 4 0.33
25. c.4242+1GNT 4374+1GNT In23 4 0.33
26. c.1000CNT R334W*# Ex7 3 0.25
27. c.1767-?_2619+?del CFTRdele13,14a Ex13–Ex14a 3 0.25
28. c.3468+2_3468+3insT 3600+2insT In18 3 0.25
29. c.3469-?_3717+?dup CFTRdup19 Ex19 3 0.25
30. c.3964-78_4242+577del CFTRdele22,23# Ex22–Ex23 3 0.25
31. c.53+1GNT 185+1GNT In1 2 0.17
32. c.54-1161_164+1603del2875 CFTRdele2 Ex2 2 0.17
33. c.169TNG W57G Ex3 2 0.17
34. c.254GNA G85E*# Ex3 2 0.17
35. c.274GNT E92X# Ex4 2 0.17
36. c.328GNC D110H# Ex4 2 0.17
37. c.579+3ANG 711+3ANG# In5 2 0.17
38. c.3528delC 3659delC*# Ex19 2 0.17
39. c.4127_4131delTGGAT 4259del5 Ex22 2 0.17
40. c.1-?_1584+?del CFTRdele1,10 Ex1–Ex10 1 0.08
41. c.115CNT Q39X# Ex1 1 0.08
42. c.79GNC G27R Ex2 1 0.08
43. c.[125CNT]+[223CNT] S42F/R75X# Ex2/Ex3 1 0.08
44. c.164+1GNA 296+1GNA In2 1 0.08
45. c.274GNA E92K# Ex4 1 0.08
46. c.349CNT R117C*# Ex4 1 0.08
47. c.509GNA R170H Ex5 1 0.08
48. c.533GNA G178E Ex5 1 0.08
49. c.579+1GNT 711+1GNT*# In5 1 0.08
50. c.902ANG Y301C Ex7 1 0.08
51. c.1040GNA R347H*# Ex7 1 0.08
52. c.1114CNT Q372X Ex7 1 0.08
53. c.1117-1GNA 1249-1GNA In7 1 0.08
54. c.1209+1GNA 1341+1GNA# In8 1 0.08
55. c.1519_1521delATC I507del*# Ex10 1 0.08
56. c.1654CNT Q552X# Ex11 1 0.08
57. c.1673TNC L558S# Ex11 1 0.08
58. c.1679+1GNC 1811+1GNC In11 1 0.08
59. c.1687TNC Y563H Ex12 1 0.08
60. c.1753GNT E585X# Ex12 1 0.08
61. c.1766+1GNC 1898+1GNC In12 1 0.08
62. c.2044delA 2176delA Ex13 1 0.08
63. c.2051_2052delAAinsG 2183delAANG# Ex13 1 0.08
64. c.2052delA 2184delA*# Ex13 1 0.08
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Table 1 (continued)
Mutations/HGVS nomenclature/ Mutations/traditional nomenclature, legacy name/ Legacy exon/intron No. of alleles %
65. c.2290CNT R764X# Ex13 1 0.08
66. c.2490+1GNA 2622+1GNA# In13 1 0.08
67. c.2538GNA W846X*# Ex14a 1 0.08
68. c.2551CNT R851X# Ex14a 1 0.08
69. c.2589_2599delAATTTGGTGCT 2721del11 Ex14a 1 0.08
70. c.2705delG 2837delG Ex15 1 0.08
71. c.2789delG 2921delG Ex15 1 0.08
72. c.2803_2813delCTACCACTGGT 2935del11 Ex15 1 0.08
73. c.2856GNC M952I Ex15 1 0.08
74. c.2991GNC L997F# Ex17a 1 0.08
75. c.3106delA 3238delA Ex17a 1 0.08
76. c.3136GNT E1046X Ex17a 1 0.08
77. c.3139GNC G1047R Ex17a 1 0.08
78. c.3196CNT R1066C*# Ex17b 1 0.08
79. c.3196CNG R1066G Ex17b 1 0.08
80. c.3302TNG M1101R Ex17b 1 0.08
81. c.3310GNA E1104K Ex17b 1 0.08
82. c.3353CNT S1118F Ex17b 1 0.08
83. c.3472CNT R1158X*# Ex19 1 0.08
84. c.3587CNG S1196X# Ex19 1 0.08
85. c.3708delT 3840delT Ex19 1 0.08
86. c.3937CNT Q1313X# Ex21 1 0.08
87. c.3971TNC L1324P Ex22 1 0.08
88. c.4003CNT L1335F Ex22 1 0.08
89. c.4004TNC L1335P Ex22 1 0.08
90. c.4097TNA I1366N Ex22 1 0.08
91. c.4426CNT Q1476X Ex24 1 0.08
92. Unknown 6 0.50
Total 1200 100.00
Legend: Within the traditional nomenclature column: “*” mutations included in the Elucigene CF-EU2v1™ assay; “#” genotype–phenotype correlations of detected
mutations are described in the CFTR2 database [21] with e.g. D1152H, L997F having “varying consequences”¨; “?” — Genomic position of breakpoints has not been
identified, thus far. Novel mutations are formatted in bold and “&” the novel mutation 3141del9 was independently detected in five unrelated CZ families.
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Altogether we found 91 different CFTR mutations (Table 1),
with only seven being present at a frequency N1%: F508del
(67.42%), CFTRdele2,3(21kb) (5.75%), G551D (2.92%),
N1303K (2.42%), G542X (2.0%), 3849+10kbCNT (1.67%)
and 1898+1GNA (1.42%) (using the legacy/traditional no-
menclature). More than half of all mutations (n=52) occurred
within a single family. In addition, 20 novel mutations (Table 1)
and a novel variant (S1456N) were discovered.
A de novo novel mutation 3840delT was detected on
“fingerprinting-proven” paternal CFTR allele in an adolescent
male patient who bears a second novel mutation in compound
heterozygosity — 3840delT/2921delG. He was diagnosed
clinically at 3 years of age (sweat test: 80 mmol/l), and suffers
from chronic Pseudomonas aeruginosa colonization and
pancreatic insufficiency.
In addition, we observed the previously described V754M
mutation in trans to N1303K in an unaffected mother (sweat
test: 40 mmol/l). Her first CF child bears a R709Q-E292K/
N1303K in trans, while sequencing of exon 7, 13 and 21 during
prenatal diagnosis of her second child, who is unaffected,
revealed the R709Q-E292K/V754M genotype.The S1455X mutation was observed in compound hetero-
zygosity with the F508del in a male patient who was clinically
diagnosed at age 7 years, in which “repeated bronchitis” led to
sweat testing (mean concentration 70 mmol/l). Interestingly,
the patient's asymptomatic father bears mutation S1455X in
trans to a novel variant S1456N and the patient's apparently
healthy brother has the maternal-F508del/S1456N genotype.
In aggregate, we identified 99.50% of all mutations (1194/
1200 CFTR alleles) in the CZ CF population (Table 1).
4. Discussion
This study presents a comprehensive overview of the CFTR
mutation distribution in a representative cohort of CZ CF
patients originating from all CZ regions (Fig. 1). Integration of
CF clinical expertise with DNA diagnostics at the Prague
National Reference Center, together with consistent application
of consensus CF clinical and laboratory diagnostic criteria, led
to the identification of more than 99% of all CFTR mutations
(Table 1).
There are over 10 million inhabitants in the country, which
according to population genetic analyses, is a representative of
the CE ethnic composition [3], with significant overlaps with
Table 2



























c.1521_1523delCTT F508del 67.42 66.80 70.00 74.00 74,60 70.30 57.0
c.54-5940_273+10250del21 kb CFTRdele2,3/21kb 5.75 2.26 5.00 1.2* 2.6# NA 1.80
c.1652GNA G551D 2.91 b0.50 0.00 6.40 1.60 2.50 0.50
c.3909CNG N1303K 2.42 2.03 5.00 2.40 0.00 NA 1.80
c.1624GNT G542X 2.00 4.06 3.75 3.20 2.40 5.10 2.60
c.3718-2477CNT 3849+10kbCNT 1.67 4.28 0.00 NA 0.00 3.40 2.70
c.1766+1GNA 1898+1GNA 1.42 b0.50 0.00 NA 0.00 NA NA
c.1040GNC R347P 0.92 1.10 1.25 0.80 1.60 2.50 NA
c.2012delT 2143delT 0.92 1.10 0.00 NA 0.00 NA NA
c.3140-26ANG 3272-26ANG 0.67 b0.50 0.00 NA 0.00 NA NA
c.3846GNA W1282X 0.58 b0.50 0.00 NA 0.00 NA 0.70
c.1007TNA I336K 0.58 0.00 0.00 NA 0.00 NA NA
c.1657CNT R553X 0.50 0.90 0.00 1.20 0.00 NA 1.90
c.2657+5GNA 2789+5GNA 0.50 0.00 0.00 NA 2.40 NA NA
c.2834CNT S945L 0.50 0.00 0.00 NA 0.00 NA NA
c.2052_2053insA 2184insA 0.42 1.58 5.00 NA 0.00 NA NA
Legend: data for Slovakia [12], Eastern Hungary [14], Germany–Bavaria [13], Austria–Tyrol [18], Austria North East and North West [13], Poland and *[8], and #
[16]. NA: not analyzed/data not available. N: number of analyzed CF alleles.
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degree, with its PL and DE Saxony neighbors [5]. Therefore,
our data are pertinent to the related populations with lower
mutation detection rates (Table 2) [8,12,13], with the exception
of Eastern HU [14]. The CZ mutation distribution is also
relevant to the North American “Bohemian diaspora” (residing
mainly in Canada and the U.S. Midwest) consisting of over
1.2 million immigrants with descendants from historical CZ
territories [15].
In the CE population, the frequency of the F508del mutation
does not “rigorously” follow the expected “North-to-South”
gradient, which could be due to the higher population heteroge-
neity in PL (Table 2). The “Slavic” mutation CFTRdele2,3/21kb/
[16] is relatively common in CE (Table 2). However, the G551D
mutation is more common within the “core Hallstatt culture
territory” [17] that comprises the current CZ, DE, AT and AT–
Tyrol [18, Table 2]. Therefore, a “Celtic” origin of G551D is likely
and is supported by its common origin and extrapolated “age” [19].
Similarly, we presume that the “Mediterranean” mutation G542X
[8] is, according to historical patterns of CE colonization [17], the
most prevalent in the Danube basin, i.e. in SK, HU, AT and DE.
In the CZ population the commercial assay Elucigene
CF-EU2v1™ achieved mutation detection rates of 90.7%,
MLPA added 1.0%, with the CFTRdele2,3/21 kb/mutation
(5.75%) being independently confirmed by this assay. Mutation
scanning and/or sequencing detected an extra 94 CF alleles,
adding an additional 7.8%.
We have not included the male with the S1455X/F508del in
our cohort, since he only suffers from “isolated elevated sweat
chloride concentrations” [20] and does not meet the diagnostic
criteria for CF [10]. Similarly, all cases with the R117H-IVS8 T(7)
in cis, which did not meet the diagnostic criteria were also
excluded from this study. Although the V754M mutation “is still
under evaluation” in the CFTR2 database [21], we concluded thatits pathogenic potential is limited. All “equivocal” cases have been
enrolled into a long-term clinical monitoring program at our center
[6,22].
The previously reported pathological L1-mediated retro-
transpositional event [23] was detected in one patient who was
compound heterozygous for the E92K/M952I mutations. It is
likely that the pathogenetic impact of the “CFTR-related disorder
associated” mutation M952I [22] was augmented by the Alu1-
related molecular alternation of theCFTR, leading to a “classical”
presentation of CF in this case.
The observed de novo novel mutation occurred on the
paternal CFTR allele (father's age at conception was 25 years)
at a rate of 1 in 1200 CFTR alleles examined, i.e. as previously
reported [24].
In addition, previously unknown complex allele [25] com-
prising R709Q-E292K in cis in four unrelated families was
discovered, with the R709Q being reported in AT [26].
In summary, we present a thorough overview of the CFTR
mutation distribution in the CZ population, which demonstrates
that integrated clinical and laboratory expertise [22] can yield
very high mutation detection rates.
The Elucigene CF-EU2v1™ assay was shown to achieve
sufficient mutation detection rates formulti-tier CFNBS (i.e. more
than 85%), although the I336K and S945L, with frequency over
0.5% (Table 1), should also be included in the Czech national
screening panel [1]. The CZ mutation distribution is relevant to
related populations which have reported rather limited mutation
spectra (e.g. Northern AT) and to the sizeable North American
immigrant population derived from this part of CE.
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